[Hematopoietic malignancy (leukemia, malignant lymphoma, multiple myeloma)].
Hematopoietic malignancies, including leukemia, lymphoma and multiple myeloma, are classified and predicted a prognosis by morphologic, cytogenetic and molecular features. With advances in molecular targeted therapy and hematopoietic stem cell transplantation, monitoring of minimal residual disease (MRD) is required for evaluation of an optimal response to therapy and early detection of disease relapse. Analysis of immunophenotypes and chimeric fusion genes characteristic for hematopoietic malignant cells are clinically useful biomarkers to classify into subtype at diagnosis and monitor MRD. On the other hand, serum markers reflecting tumor burden are clinically useful to monitor the disease progression in hematopoietic malignancies: e.g., LDH and soluble IL-2 receptor for lymphoma; M-protein and free light chain for multiple myeloma.